Bristol Myers Squibb Company $BMY Shares Sold by Artemis Investment Management LLP

Artemis Investment Management LLP cut its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 7.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,823,235 shares of the biopharmaceutical company’s stock after selling 230,245 shares during the period. Bristol Myers Squibb comprises approximately 1.4% of Artemis Investment Management LLP’s portfolio, making the stock its 14th largest position. Artemis Investment Management LLP’s holdings in Bristol Myers Squibb were worth $176,170,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Apella Capital LLC raised its position in shares of Bristol Myers Squibb by 159.2% during the third quarter. Apella Capital LLC now owns 33,162 shares of the biopharmaceutical company’s stock worth $2,069,000 after acquiring an additional 20,370 shares during the last quarter. Everhart Financial Group Inc. raised its holdings in Bristol Myers Squibb by 2.2% during the 3rd quarter. Everhart Financial Group Inc. now owns 21,496 shares of the biopharmaceutical company’s stock worth $1,341,000 after purchasing an additional 456 shares during the last quarter. Avidian Wealth Enterprises LLC lifted its position in shares of Bristol Myers Squibb by 28.0% in the 3rd quarter. Avidian Wealth Enterprises LLC now owns 16,342 shares of the biopharmaceutical company’s stock worth $1,020,000 after purchasing an additional 3,576 shares during the period. Valeo Financial Advisors LLC boosted its stake in shares of Bristol Myers Squibb by 21.3% in the 3rd quarter. Valeo Financial Advisors LLC now owns 36,135 shares of the biopharmaceutical company’s stock valued at $2,255,000 after purchasing an additional 6,351 shares during the last quarter. Finally, Vann Equity Management LLC acquired a new stake in shares of Bristol Myers Squibb during the third quarter worth $296,000. Institutional investors own 76.41% of the company’s stock.

Insider Buying and Selling at Bristol Myers Squibb

In related news, SVP Phil M. Holzer sold 500 shares of Bristol Myers Squibb stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the transaction, the senior vice president owned 16,862 shares of the company’s stock, valued at $1,138,185. The trade was a 2.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.05% of the stock is owned by corporate insiders.

Bristol Myers Squibb Stock Down 0.5%

BMY stock traded down $0.28 during midday trading on Thursday, reaching $59.41. 3,481,988 shares of the company’s stock traded hands, compared to its average volume of 11,964,922. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. The firm’s fifty day moving average price is $64.38 and its 200-day moving average price is $60.27. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $68.64. The company has a market cap of $121.37 billion, a price-to-earnings ratio of 13.09, a P/E/G ratio of 0.28 and a beta of 0.19.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. The firm had revenue of $12.97 billion during the quarter, compared to analysts’ expectations of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The business’s revenue was up 5.7% on a year-over-year basis. During the same period last year, the company earned $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, sell-side analysts forecast that Bristol Myers Squibb Company will post 6.95 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. The ex-dividend date of this dividend is Friday, October 2nd. Bristol Myers Squibb’s payout ratio is currently 55.51%.

Analyst Ratings Changes

A number of brokerages have weighed in on BMY. Raymond James Financial started coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They set a “strong-buy” rating for the company. Weiss Ratings upgraded Bristol Myers Squibb from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, August 18th. Leerink Partners cut Bristol Myers Squibb from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $73.00 to $59.00 in a report on Monday. Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 27th. Finally, Wells Fargo & Company set a $65.00 price target on shares of Bristol Myers Squibb and gave the stock an “equal weight” rating in a report on Friday, July 31st. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Bristol Myers Squibb presently has an average rating of “Moderate Buy” and a consensus price target of $66.72.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Positive Phase 3 Zenbexustm data: Bristol Myers Squibb reported that Zenbexus (iberdomide), combined with daratumumab and dexamethasone, delivered superior progression-free survival versus standard of care in relapsed and refractory multiple myeloma. The result strengthens BMY’s pipeline and could support a future growth driver in a competitive market. Bristol Myers Squibb Announces Zenbexus Phase 3 Results
• Positive Sentiment: Growth from newer medicines: Reblozyl’s strong sales and additional indications may help offset declines from older products. BMY also secured a Camzyos label expansion, potentially broadening the drug’s commercial opportunity. Reblozyl Growth Outlook
• Neutral Sentiment: Sotyktu adoption is developing unevenly: Rheumatologists are increasingly using the oral TYK2 inhibitor for psoriatic arthritis and recognize its differentiation, but limited experience, access hurdles and questions about joint efficacy are restraining its launch momentum. Sotyktu Psoriatic Arthritis Adoption
• Negative Sentiment: Analyst price-target reduction: Cantor Fitzgerald lowered its BMY target from $59 to $53 and maintained a neutral rating, signaling limited near-term upside in its view.
• Negative Sentiment: Patent-cliff concerns remain: Analysts continue to highlight the risk that patent expirations and declining legacy-drug sales could pressure revenue, increasing the importance of successful launches and pipeline development. Bristol Myers Squibb Patent Cliff Analysis

Bristol Myers Squibb Profile

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its research and commercial activities focus primarily on oncology, hematology, immunology, cardiovascular disease and neuroscience. The company serves patients and healthcare providers in the United States and international markets.

Bristol Myers Squibb’s portfolio includes medicines such as Opdivo and Yervoy for certain cancers, Eliquis for the prevention of blood clots and stroke, Revlimid and Pomalyst for blood cancers, and Abraxane for certain solid tumors.